Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

NFA_DYOR Jul. 28 at 1:23 PM

$GRI What the hell Its heading towards reverse split zones

0 · Reply

NFA_DYOR Jul. 24 at 10:13 AM

$GRI $ELAB When is next RS? I guess my avarage will go high

0 · Reply

NFA_DYOR Jul. 24 at 10:12 AM

$GRI $ELAB Why zero insider ownership and under 2% institutional ownership? Thats a sign of confidence that 100% is owned by retail.

0 · Reply

NFA_DYOR Jul. 23 at 9:03 PM

$GRI Insider ownership- 0% Institutional ownership <2% Mostly owned by @Joe_088

0 · Reply

NFA_DYOR Jul. 23 at 11:57 AM

$GRI When is next riverse split? I wonder what ratio it'll be

0 · Reply

NFA_DYOR Jul. 22 at 9:47 AM

$GRI Imagine you fomoed and thought this isbon it way to $200

0 · Reply

NFA_DYOR Jul. 21 at 12:28 PM

$GRI Bro What the hell You said next stop is $16 I only see it going down Whats tour advise? Sell or stay?

1 · Reply

NFA_DYOR Jul. 20 at 10:56 PM

$GRI I'd rather follow basement teenager who thinks analystically than a mastermind who studied deceit with fomo and other psychological tactics

0 · Reply

NFA_DYOR Jul. 20 at 10:54 PM

$GRI How many dilutions? How many RS? When is next phase? How much would that phase cost? How much cash do they have? When is next/ongoing dilution? Those are qusstions i ask! You and @Joe_088 only say: Last train to moon! Next nvidia! Next stop $60, or $200 You are paid pumpers, to mislead others.

0 · Reply

NFA_DYOR Jul. 20 at 8:51 PM

$GRI Bo bo doesnt mislead people You do,

0 · Reply

GRI Bio announces U.S. FDA granted ODD to GRI-0621

Jun 18, 2026, 8:31 AM EDT - 6 weeks ago

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

2026-06-17T15:00:10.000Z - 6 weeks ago

GRI Bio granted FDA orphan designation for tazarotene

May 18, 2026, 9:15 AM EDT - 2 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2026, 8:35 AM EDT - 2 months ago

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

May 13, 2026, 7:00 AM EDT - 2 months ago

GRI Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

GRI Bio Earnings release: Q1 2026

2026-04-08T13:21:10.000Z - 4 months ago

GRI Bio receives UAE patent allowance for inflammatory disease treatments

Apr 8, 2026, 8:30 AM EDT - 4 months ago

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Mar 6, 2026, 6:00 AM EST - 5 months ago

GRI Bio Slides: Corporate presentation

Feb 17, 2026, 9:15 AM EST - 5 months ago

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Feb 11, 2026, 1:00 PM EST - 6 months ago

GRI Bio Transcript: Corporate Connect Webinar Series

Feb 5, 2026, 9:15 AM EST - 6 months ago

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

2026-02-04T13:50:33.000Z - 6 months ago

GRI Bio sees cash runway into 1Q27

Feb 4, 2026, 8:45 AM EST - 6 months ago

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Feb 4, 2026, 8:30 AM EST - 6 months ago

GRI Bio Earnings release: Q4 2025

Feb 4, 2026, 8:30 AM EST - 6 months ago

GRI Bio Annual report: Q4 2025

Jan 30, 2026, 7:00 AM EST - 6 months ago

GRI Bio Registration statement: Registration Filing

2026-01-30T11:11:17.000Z - 6 months ago

GRI Bio files $250M mixed securities shelf

2026-01-28T14:41:21.000Z - 6 months ago

GRI Bio Inc trading resumes

2026-01-28T14:35:28.000Z - 6 months ago

GRI Bio Inc trading halted, volatility trading pause

2026-01-28T13:56:26.000Z - 6 months ago

GRI Bio delivers additional data from Phase 2a study of GRI-0621

Jan 28, 2026, 8:45 AM EST - 6 months ago

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

2026-01-26T13:35:51.000Z - 6 months ago

GRI Bio secures U.S. composition of matter patent

2026-01-24T00:50:50.000Z - 6 months ago

GRI Bio Inc trading halted, news pending

2026-01-21T21:25:40.000Z - 6 months ago

GRI Bio announces 1-for-28 reverse stock split

Jan 21, 2026, 4:01 PM EST - 6 months ago

GRI Bio Announces Reverse Stock Split

Jan 15, 2026, 9:00 AM EST - 7 months ago

GRI Bio Transcript: EGM 2026

2026-01-08T13:39:21.000Z - 7 months ago

GRI Bio announces data from Phase 2a study in Idiopathic Pulmonary Fibrosis

Dec 29, 2025, 7:00 AM EST - 7 months ago

GRI Bio Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

GRI Bio Proxy statement: Proxy Filing

Dec 12, 2025, 4:05 PM EST - 8 months ago

GRI Bio Announces Closing of $8.0 Million Public Offering

2025-12-11T14:20:13.000Z - 8 months ago

GRI Bio prices 10.67M shares at 75c in public offering

Dec 11, 2025, 9:15 AM EST - 8 months ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

2025-12-10T21:41:18.000Z - 8 months ago

GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints

Dec 10, 2025, 4:05 PM EST - 8 months ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Dec 10, 2025, 7:00 AM EST - 8 months ago

GRI Bio Registration statement: Registration Filing

2025-12-08T13:25:31.000Z - 8 months ago

GRI Bio files to sell 5.13M shares of common stock, warrants

Dec 8, 2025, 7:00 AM EST - 8 months ago

GRI Bio Registration statement: Registration Filing

Nov 14, 2025, 7:00 AM EST - 9 months ago

GRI Bio Quarterly report: Q3 2025

2025-09-11T12:50:15.000Z - 11 months ago

GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621

Sep 11, 2025, 8:45 AM EDT - 11 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 9, 2025, 3:00 PM EDT - 11 months ago

GRI Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:00 PM EDT - 1 year ago

GRI Bio Quarterly report: Q2 2025

Aug 14, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 1 year ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

2025-07-31T13:05:39.000Z - 1 year ago

GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF

Jul 22, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 11, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Jul 6, 2025, 6:00 PM EDT - 1 year ago

GRI Bio Slides: Corporate Presentation

2025-07-01T12:50:17.000Z - 1 year ago

GRI Bio completes enrollment in Phase 2a study of GRI-0621

Jul 1, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

2025-06-26T12:06:08.000Z - 1 year ago

GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621

Jun 26, 2025, 8:00 AM EDT - 1 year ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: Alliance Global Partners Healthcare Company Showcase

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 15, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

GRI Bio Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

GRI Bio Earnings release: Q1 2025

May 8, 2025, 8:45 AM EDT - 1 year ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 1 year ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 1 year ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Mar 31, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 26, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Registration statement: Registration Filing

Mar 25, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Registration statement: Registration Filing

Mar 18, 2025, 9:05 AM EDT - 1 year ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 1 year ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 14, 2025, 7:30 AM EDT - 1 year ago

GRI Bio Earnings release: Q4 2024

Mar 14, 2025, 7:30 AM EDT - 1 year ago

GRI Bio Annual report: Q4 2024

Mar 11, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Jan 17, 2025, 7:00 AM EST - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Jan 7, 2025, 7:00 AM EST - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 6, 2024, 7:00 AM EST - 1 year ago

GRI Bio Slides: Corporate Presentation

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Registration statement: Registration Filing

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 2 years ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 14, 2024, 8:05 AM EDT - 2 years ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Slides: Q2 2024

Aug 2, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Jul 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Jul 15, 2024, 9:05 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 2 years ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 2 years ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 26, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Registration statement: Registration Filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Registration statement: Registration Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Registration statement: Registration Filing

May 22, 2024, 9:15 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 2 years ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

NFA_DYOR Jul. 28 at 1:23 PM

$GRI What the hell Its heading towards reverse split zones

0 · Reply

NFA_DYOR Jul. 24 at 10:13 AM

$GRI $ELAB When is next RS? I guess my avarage will go high

0 · Reply

NFA_DYOR Jul. 24 at 10:12 AM

$GRI $ELAB Why zero insider ownership and under 2% institutional ownership? Thats a sign of confidence that 100% is owned by retail.

0 · Reply

NFA_DYOR Jul. 23 at 9:03 PM

$GRI Insider ownership- 0% Institutional ownership <2% Mostly owned by @Joe_088

0 · Reply

NFA_DYOR Jul. 23 at 11:57 AM

$GRI When is next riverse split? I wonder what ratio it'll be

0 · Reply

NFA_DYOR Jul. 22 at 9:47 AM

$GRI Imagine you fomoed and thought this isbon it way to $200

0 · Reply

NFA_DYOR Jul. 21 at 12:28 PM

$GRI Bro What the hell You said next stop is $16 I only see it going down Whats tour advise? Sell or stay?

1 · Reply

NFA_DYOR Jul. 20 at 10:56 PM

$GRI I'd rather follow basement teenager who thinks analystically than a mastermind who studied deceit with fomo and other psychological tactics

0 · Reply

NFA_DYOR Jul. 20 at 10:54 PM

0 · Reply

NFA_DYOR Jul. 20 at 8:51 PM

$GRI Bo bo doesnt mislead people You do,

0 · Reply

Absurdity54 Jul. 20 at 8:49 PM

$GRI This post is 80% YOGI (NFA_DYOR) LMAO....Basement teenager

0 · Reply

Absurdity54 Jul. 20 at 8:47 PM

$GRI NFA_DYOR....This guy advocates for you to do your own research (DYOR) yet denies the professional analysts research. Don't know what his plan is. Perhaps to drive the price down for cheapies before the FDA approvals. Just another ignorant BEAR..I'm calling him Yogi...

0 · Reply

NFA_DYOR Jul. 20 at 8:41 PM

$GRI Still misinformation

1 · Reply

NFA_DYOR Jul. 20 at 8:41 PM

$GRI H.c. Wainwright gives aggressive abalyst whilst the same time they are making an aggressive toxic finance

0 · Reply

NFA_DYOR Jul. 20 at 8:40 PM

$GRI Why are you giving people wrong financial advice

0 · Reply

Absurdity54 Jul. 20 at 8:37 PM

$GRI https://stockanalysis.com/stocks/gri/forecast/

0 · Reply

NFA_DYOR Jul. 19 at 2:48 PM

$GRI @Absurdity54 These are the pumpers you should sue if you are bleeding. They give financial misinformation whilst you are bleeding

3 · Reply

NFA_DYOR Jul. 19 at 2:46 PM

$GRI Imagine @Joe_088 promised $12 or more but you are heavily bleeding, would you sue them for financial misinformation?

0 · Reply

NFA_DYOR Jul. 18 at 11:51 AM

$GRI Imagine you were pumped by @Joe_088 and you kept buying whenever he said: - Next nvidia - slap that ask - diamond hands - rocketing - moon is next stop - last train, get in on time Now you are heavily bleeding You could start suing

0 · Reply

NFA_DYOR Jul. 17 at 11:39 AM

$GRI You think conpanies wait until they have zero days before they dolute? They plan massive dilutions betaeen 5-9 months ahead and by 6 months to runway if no dilution its too late

0 · Reply

ka1954 Jul. 17 at 10:33 AM

$GRI the price action is a piece of crap. now going down more due to market crashing, fucked up stock

0 · Reply

NFA_DYOR Jul. 17 at 9:07 AM

$GRI Its juat phase 2a They need cash to run years of operations

1 · Reply

Market Cap	2.44M
Revenue (ttm)	0.00
Net Income (ttm)	-11.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	23,700
Avg Vol	70,530
Day's Range	N/A - N/A
Shares Out	1.77M
Stochastic %K	10%
Beta	-1.21
Analysts	Sell
Price Target	$21.00